External Positions
- Renal Association nominated Clinical Expert - commented on scope and then provided evidence for the appraisal. Meeting in May 2021https://renal.org/health-professionals/consultations/belimumab-treating-active-autoantibody-positive-systemic-lupus, NICE STA Belimumab for the treatment of SLE, NICE, 2020
- Member, Data Monitoring Committee, TACTIC-R trial, TACTIC-R Trial - mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs - https://clinicaltrials.gov/ct2/show/NCT04390464, 2020
- Abstract Category Chair for Women's Health and Kidney Diseases, Kidney Week programme committee sub committee, American Society of Nephrology, 2020 - 2020
- Co-Chair, Renal Association COVID-19 working group for advice on shielding and unshielding of non-transplant immunosuppressed renal patients, Renal Association, 2020
- Elected member, Executive Council Women in Nephrology, Women in Nephrology, 2019 - 2020
- Trustee, Kidney Research UK Board of Trustees, Kidney Research UK, 2018 - 2021
- Co-Chair, Steering Committee, SONG-GN Executive Committee, SONG Initiative, 2018
- Chair, World Kidney Day 2018 Planning Group, British Renal Association, 2018
- Member, Can-SOLVE CKD International Research Advisory Committee (CIRAC), Can-SOLVE CKD ($40million programme), 2017 - 2022
- Member Co wrote guideline, Pregnancy and Renal Disease Guideline working group, Renal Association, 2017 - 2019
- Faculty member, Glomerular disease early program committee, American Society of Nephrology, 2016 - 2016
- Co-opted member (Renal), NICE Guideline Committee on Intrapartum Care for High Risk Women with Medical Conditions, Royal College of Obstetricians and Gynaecologists, 2016
- Co-Chair, UKKRC Glomerulonephritis Clinical Study Group, UK Kidney Research Consortium, 2013
- Inaugural National Coordinator Jan 2013-Dec 2014. Committee member 2014 onwards, RaDaR Pregnancy and Chronic Kidney Disease Rare Disease Group, RaDaR - Rare Renal https://renal.org/rare-renal/homepage, 2013
- Clinical specialist - nominated by the Renal Association; responded to Scoping exercise, provided commentary for the consultation and was one of two clinical specialists invited to the Committee discussions and to respond to the ACD. This has been a long process due to appeals and is still ongoing, NICE STA on Belimumab for the Treatment of Lupus, NICE, 2011
- Member, LUPUS UK Peer review panel, LUPUS UK, 2010
- North West Thames representative, NIHR CRN renal speciality group, NIHR CRN, 2008 - 2012
- Speciality Group lead for Renal Medicine, NW London CLRN, 2008 - 2012
- Renal Lead for West London, UK Kidney Research Consortium, UK Kidney Research Consortium, 2008
- Member, RCOG 54th Study Group Renal Disease in Pregnancy, RCOG, 2007 - 2008
- CSM/MCA Expert Advisory Panel, Committee of Safety of Medicine, 2004
- Co-Chair, Working Group for Module 3 (prevention of Kidney Disease) of the National Service Framework in Renal Disease, 2002
- Founding Member, Lupus Nephritis Study Group, British Society of Rheumatology/BILAG/Renal Association, 2000
- Founder and Member of ABLE Advisory Committee, Member of External Referee Panel, National Kidney Research Fund, 2000
- Specialist medical advisor, National Kidney Research Fund ABLE Programme, 2000
Membership of Professional Bodies
- Collaborating for a Cure -, Invitation only meeting in New York 2013 - organised by the Lupus Research Institute in partnership with the Lupus Nephritis Trials Network. This meeting marks the launch of the Lupus Nephritis Trials Network, which has as its mission enhancing the scientific basis of nephritis trials., 2013 - 2013
- National Coordinator, Pregnancy and Chronic Kidney Disease Rare Disease Group, part of the Rare Renal Disease, The Pregnancy and Chronic Kidney Disease Rare Disease Group is a newly established group within the Rare Renal Disease Initiative - the aim is to provide patient information, generate a national registry of all women with chronic kidney disease who have pregnancies, provide guidelines for management and be a hub for generating research and linking sites., 2012
- Member, Renal Association Annual Meeting programme committee, Member of the committee planning the annual RA meeting - national meeting of the RA and variously joint with the British Transplant Society (2013), British Renal Society (2014) and free standing (2012), 2011
- Elected member, Renal Association Executive, Renal Association, 2009 - 2012
Links with Other Academic Bodies
- Lupus Nephritis Trials Network (LNTN) - member, EU executive, LNTN, 2012
- RITUXILUP - Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis, Imperial College London and Imperial College Clinical Trials Unit, 2012 - 2013
Industrial Connections
- Anthera pharmaceuticals inc., Member of advisory board - providing expertise on clinical trials in Lupus nephritis
- Aspreva, European Lupus Advisory Board
- Aurinia, Scientific Consultant with expertise in glomerulonephritis
- Biogen Idec, Advisor on development of Clinical Trial in Lupus Nephritis - The Atlas TrialPotential collaboration on imaging in renal inflammation
- Medimmune, Chair, Advisory Board on Lupus Nephritis
- Merck, Sharpe and Dohme Ltd, Advisor, SLE Scientific Input Engagement - invited as international expert on management of lupus nephritis, particularly with respect to biologics. Contributed to a 1.5 day detailed meeting - one of 4 international clinical advisors and the only nephrologist. Gave talk on trials of biologics in lupus nephritis as well as contributed throughout the day.
- Roche, Lupus Advisory Board
- Roche / Genentech, Provision of global support to Rituxilup Trial to provide the trial drug Rituximab (~1m Euros) and provision of support to US sites ($600,000)Drug provision Agreed in principle 2.3.2012 and US sites 12.8.2013. Awaiting final protocol approval August 2013
- TevaPharm, Chair, Trial Steering Committee, Phase III Multicenter Randomised Placebo-Controlled, Double-Blinded Study combining a dose selection with a sample size reestimation assessing efficacy, safety and tolerability of Laquinimod or placebo in Combination with MMF and steroids in patients with Active Lupus Nephritis.
- Vifor, Advisor on development of trial using a CNI in lupus nephritis
Fellowships
- MRC Training Fellowship, Medical Research Council
- Fellow, Royal College of Physicians
- MRC Clinician Scientist Fellowship, Medical Research Council
Editorial Boards
- Nature Reviews Nephrology, Member, Advisory Board
- Wiley's Evidence Based Nephrology, second edition, Section Editor, 2018 - 2020